MicroRNA startup Causeway targets raise after results of tendinopathy studynews2025-10-27T13:00:06+00:00October 27th, 2025|Endpoints News|
BridgeBio shifts filing plans for rare disease drug after Phase 3 successnews2025-10-27T11:00:42+00:00October 27th, 2025|Endpoints News|
Neumora moves forward with NLRP3 in obesity after Ventyx’s drug failed to deliver weight lossnews2025-10-27T10:30:05+00:00October 27th, 2025|Endpoints News|
Eli Lilly to seek Olumiant approval in adolescents with alopecianews2025-10-24T14:17:22+00:00October 24th, 2025|Endpoints News|
Remix reveals first signs of tumor shrinkage with small molecule mRNA degradernews2025-10-24T14:00:54+00:00October 24th, 2025|Endpoints News|
Merus makes push into colorectal cancer with early positive datanews2025-10-24T14:00:03+00:00October 24th, 2025|Endpoints News|
Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltranews2025-10-24T13:00:14+00:00October 24th, 2025|Endpoints News|
Inhibrx will head to FDA for bone cancer drug next year after strong datanews2025-10-23T20:05:22+00:00October 23rd, 2025|Endpoints News|
Icon warns of macro environment headwinds as Medpace maintains revenue momentumnews2025-10-23T15:18:35+00:00October 23rd, 2025|Endpoints News|
Tango to advance pancreatic cancer drug into Phase 3, raises $225Mnews2025-10-23T15:06:00+00:00October 23rd, 2025|Endpoints News|
